May 28, 2017 4:10 PM ET

Biotechnology

Company Overview of Celldex Therapeutics, Inc.

Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing ...

Perryville III Building

Suite 200

53 Frontage Road

Hampton, NJ 08827

United States

205 Employees

Phone:

908-200-7500

Fax:

908-454-1911

Key Executives for Celldex Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $859.4K
Founder, Chief Scientific Officer and Executive Vice President
Age: 57
Total Annual Compensation: $548.8K
CFO, Principal Accounting Officer, Senior VP, Treasurer and Secretary
Age: 68
Total Annual Compensation: $442.2K
Chief Medical Officer and Executive Vice President
Age: 52
Total Annual Compensation: $572.1K
Chief Business Officer and Senior Vice President
Age: 60
Total Annual Compensation: $435.1K
Compensation as of Fiscal Year 2016.

Celldex Therapeutics, Inc. Key Developments

Celldex Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended of March 31, 2017

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended of March 31, 2017. For the quarter, the company’s total revenue was $1.5 million compared to $1.3 million for the comparable period in 2016. The increase in revenue was primarily due to the clinical trial collaboration with Bristol-Myers Squibb and the research and development agreement with Rockefeller University. Net loss was $34.3 million, or $0.28 per share, for the first quarter of 2017, compared to a net loss of $34.7 million, or $0.35 per share, for the comparable period in 2016. Operating loss was $35,112,000 compared to $35,704,000 a year ago.

Celldex Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2016

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2016. For the quarter, the company’s total revenue was $1,874,000 compared to $1,790,000 a year ago. Net loss was $32,307,000 or $0.30 per basic and diluted share compared to a $32,684,000 or $0.33 per basic and diluted share a year ago. Operating loss was $34,852,000 compared to $33,438,000 a year ago. The increase in revenue was primarily due to clinical trial collaboration with Bristol-Myers Squibb and an increase in grant revenue, partially offset by a decrease in revenue from research and development agreement with Rockefeller University. Cash used in operating activities was approximately $20.3 million. For the year, the company’s total revenue was $6,786,000 compared to $5,480,000 a year ago. Net loss was $128,530,000 or $1.27 per basic and diluted share compared to $127,197,000 or $1.31 per basic and diluted share a year ago. Operating loss was $132,916,000 compared to $129,541,000 a year ago.

Celldex Therapeutics, Inc Appoints James J. Marin to Board of Directors

Celldex Therapeutics, Inc. announced the appointment of James J. Marino, J.D., to the company's Board of Directors. Mr. Marino was with the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office. Mr. Marino currently serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center and on the Board of Directors of Onconova Therapeutics, Inc.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 1, 2016
Kolltan Pharmaceuticals, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celldex Therapeutics, Inc., please visit www.celldextherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.